Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Bernal-Mizrachi Leon; Cole Craig E.; Heffner Leonard; Nooka Ajay K.; Vij Ravi; Kelkar Nyaya; Sridhar Akshata; Cinar Munevver; Chen Zhengjia; Chang Zhao; Lonial Sagar; Kaufman Jonathan L.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

【24h】

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

机译：IXAZOMIB和地塞米松的II期试验与IXAZOMIB，地塞米松和Lenalidomide，随机用NFKB2重排。（蛋白酶体抑制剂NFKB2重排驱动试验，PINR）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology 》 |2018年第novaelatreatmentappr期| 共3页
作者
Bernal-Mizrachi Leon; Cole Craig E.; Heffner Leonard; Nooka Ajay K.; Vij Ravi; Kelkar Nyaya; Sridhar Akshata; Cinar Munevver; Chen Zhengjia; Chang Zhao; Lonial Sagar; Kaufman Jonathan L.;
展开▼
作者单位

Emory Univ Winship Canc Inst Dept Hematol &

Med Oncol Atlanta GA 30322 USA;

Univ Michigan Div Hematol Oncol Ann Arbor MI 48109 USA;

Emory Univ Sch Med Dept Hematol &

Med Oncol Emory TX USA;

Emory Univ Sch Med Dept Hematol &

Med Oncol Winship Canc Inst Atlanta GA USA;

Washington Univ Sch Med St Louis MO USA;

Empire Genom Buffalo NY USA;

Emory Univ Winship Canc Inst Atlanta GA 30322 USA;

Emory Univ Winship Canc Inst Atlanta GA 30322 USA;

Emory Univ Dept Biostat &

Bioinformat Atlanta GA 30322 USA;

Emory Univ Dept Biostat &

Bioinformat Shared Resource Winship Canc Inst Atlanta GA 30322 USA;

Emory Univ Sch Med Dept Hematol &

Med Oncol Winship Canc Inst Atlanta GA USA;

Emory Univ Sch Med Dept Hematol &

Med Oncol Winship Canc Inst Atlanta GA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病 ;
关键词

相似文献

外文文献
中文文献

1. Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) [J] . Bernal-Mizrachi Leon, Cole Craig E., Heffner Leonard, Blood: The Journal of the American Society of Hematology . 2018 ,第NovaelaTreatmentAppr期

机译：IXAZOMIB和地塞米松的II期试验与IXAZOMIB，地塞米松和Lenalidomide，随机用NFKB2重排。（蛋白酶体抑制剂NFKB2重排驱动试验，PINR）
2. Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial [J] . Zweegman Sonja, Schjesvold Fredrik H., van der Holt Bronno, Blood: The Journal of the American Society of Hematology . 2018 ,第NovaelaTreatmentAppr期

机译：IXAZOMIB-羟胺 - 低剂量地塞米松（ITD）诱导随后在新诊断的多发性骨髓瘤患者中与IXAZOMIB或安慰剂进行维持治疗，没有资格获得自体干细胞移植; 随机阶段II Hovon-126 / NMSG 21＃13试验结果
3. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma [J] . Marc-Andrea Baertsch, Jana Schlenzka, Elias K. Mai, BMC Cancer . 2016 ,第1期

机译：德语德语骨髓瘤多中心小组（GMMG）试验ReLApsE的原理和设计：来那度胺/地塞米松与来那度胺/地塞米松联合随后自体干细胞移植和来那度胺维持治疗多发性骨髓瘤患者的随机，开放，多中心III期试验
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. Bayesian Sequential Randomization Designs for Phase III Clinical Trials. [D] . Zhu, Han. 2016

机译：III期临床试验的贝叶斯顺序随机设计。
6. Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial [O] . Sonja Zweegman, Claudia A.M. Stege, Einar Haukas, 2020

机译：IXAZOMIB-羟胺胺 - 低剂量地塞米松诱导随后与新诊断的多发性骨髓瘤患者的IXAZOMIB或安慰剂进行维持治疗没有资格获得自体干细胞移植;随机阶段II Hovon-126 / NMSG的结果结果来自21.13试验
7. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor [O] . Samantha Hinsley, Katrina Walker, Debbie Sherratt, 2020

机译：MUK 8方案：环磷酰胺和地塞米松的随机期II试验与Ixazomib，复发或难治性多发性骨髓瘤（RRMM）患者与亚马亚度胺，Lenalidomide和蛋白酶体抑制剂进行处理后复发

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

著录项

相似文献

相关主题

期刊订阅